Ashland(ASH)

Search documents
Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts
Seeking Alpha· 2025-01-23 12:30
Content Summary - The article promotes joining iREIT on Alpha for in-depth research on REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives, highlighting 438 testimonials with mostly 5-star ratings and offering a FREE 2-week trial [1] - President Trump was officially sworn in as the 47th President of the United States, making history as noted by The Wall Street Journal [1] Analyst's Disclosure - The analyst holds a beneficial long position in REXR through stock ownership, options, or other derivatives, and the article reflects their personal opinions without compensation (other than from Seeking Alpha) [2] Seeking Alpha's Disclosure - Seeking Alpha clarifies that past performance does not guarantee future results and does not provide investment recommendations or advice, with views expressed not necessarily reflecting those of Seeking Alpha as a whole [3]
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for
ZACKS· 2025-01-21 16:11
Wall Street expects a year-over-year decline in earnings on lower revenues when Ashland (ASH) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 28, 2025, might help the stock move higher if these key numbers are better than expecta ...
Bear of the Day: Ashland Inc (ASH)
ZACKS· 2025-01-16 13:12
Ashland Inc (ASH) is a Zacks Rank #5 (Strong Sell) after the company missed the Zacks Consensus Estimate when the last reported. The company is in the specialty chemicals space and services many industries such as the automotive and construction sectors. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.Description Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatin ...
Ashland sets date for first-quarter fiscal 2025 earnings release and conference call webcast
GlobeNewswire· 2025-01-14 12:00
WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://in ...
New Strong Sell Stocks for January 7th
ZACKS· 2025-01-07 09:26
Stocks Added to Zacks Rank 5 (Strong Sell) List - 89bio Inc (ETNB) is a clinical-stage biopharmaceutical company with a 38 8% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Altice USA Inc (ATUS) is a broadband communications and video services provider with a 250% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Ashland Inc (ASH) is an additives and specialty ingredients provider with a 16 2% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [2]
Ashland signs definitive agreement to sell Avoca business to Mane
Newsfilter· 2024-12-23 22:01
Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line ...
Ashland: A Stable Stock Trading At 50% Discount To Its Intrinsic Value
Seeking Alpha· 2024-12-12 13:22
As an investment analyst with 3 years of experience in the finance sector, I specialize in analyzing market trends, conducting thorough financial assessments, and providing actionable investment recommendations. My expertise lies in momentum and factor investing, where I utilize a blend of quantitative and qualitative methods to identify opportunities and manage risks.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate a ...
New Strong Sell Stocks for December 12th
ZACKS· 2024-12-12 10:16
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ashland Inc. (ASH) : is a additive and specialty ingredients provider. The Zacks Consensus Estimate for its current year earnings has been revised 15% downward over the last 60 days.Baidu, Inc. (BIDU) is an online marketing and cloud services provider. The Zacks Consensus Estimate for its current year earnings has been revised 9% downward over the last 60 days.Evolent Health, Inc. (EVH) is a health service company. The Zacks Consensus ...
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
GlobeNewswire News Room· 2024-12-03 13:00
HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell diseaseFRONTIER4 interim phase 3 results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks for patients with haemophilia A with or without inhibitorsExplorer7 phase 3 study results evaluating the safety profile and efficacy of concizumab in patients with haemophilia A or B with inhibitors, with or without target joints at baseline Bagsvær ...
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
GlobeNewswire News Room· 2024-12-03 12:30
SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American So ...